CLINICAL TRIALS PROFILE FOR DEOXYCHOLIC ACID
✉ Email this page to a colleague
All Clinical Trials for deoxycholic acid
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00422188 ↗ | Deoxycholic Acid Injection for the Treatment of Superficial Lipomas | Completed | Kythera Biopharmaceuticals | Phase 1 | 2007-01-01 | The purpose of this research is to compare the safety and effectiveness of 4 different concentrations of deoxycholic acid injection against a placebo in the treatment of superficial lipomas. |
| NCT00608842 ↗ | Phase 2 Study for the Treatment of Superficial Lipomas | Completed | Kythera Biopharmaceuticals | Phase 2 | 2007-11-01 | The purpose of this research is to compare the safety and effectiveness of 3 different concentrations of deoxycholic acid for injection against a placebo in the treatment of superficial lipomas. |
| NCT00618618 ↗ | Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat | Completed | Kythera Biopharmaceuticals | Phase 2 | 2008-04-01 | Phase 2 trial to evaluate the safety and potential efficacy of one concentration of deoxycholic acid injection, given in three dosing paradigms, compared to placebo for the reduction of submental fat (fat beneath the chin). |
| NCT00618722 ↗ | Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat | Completed | Kythera Biopharmaceuticals | Phase 1/Phase 2 | 2007-08-01 | To evaluate the safety and potential efficacy of deoxycholic acid injection compared to placebo for the reduction of submental fat (fat below the chin). |
| NCT00858858 ↗ | Clinical Studies on Bile Acids in Barrett's Esophagus | Completed | US Department of Veterans Affairs | N/A | 2009-03-01 | This study has two major goals: 1. To determine the effects of bile salts on causing DNA injury and activating signaling pathways that promote growth in cells from the esophagus of patients who have gastroesophageal reflux disease (GERD) 2. To determine whether changes in bile composition induced by treating patients with a bile salt called ursodeoxycholic acid (UDCA) can alter DNA injury, signaling pathway activation and other types of damage in cells from the esophagus of patients who have GERD. |
| NCT00858858 ↗ | Clinical Studies on Bile Acids in Barrett's Esophagus | Completed | VA Office of Research and Development | N/A | 2009-03-01 | This study has two major goals: 1. To determine the effects of bile salts on causing DNA injury and activating signaling pathways that promote growth in cells from the esophagus of patients who have gastroesophageal reflux disease (GERD) 2. To determine whether changes in bile composition induced by treating patients with a bile salt called ursodeoxycholic acid (UDCA) can alter DNA injury, signaling pathway activation and other types of damage in cells from the esophagus of patients who have GERD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for deoxycholic acid
Condition Name
Clinical Trial Locations for deoxycholic acid
Trials by Country
Clinical Trial Progress for deoxycholic acid
Clinical Trial Phase
Clinical Trial Sponsors for deoxycholic acid
Sponsor Name
